Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.

Abstract:

:A 68-year-old female was diagnosed with acute myeloid leukemia (AML-M2 without 8/21 translocation) in December 2006. Although a complete remission (CR) was obtained after induction chemotherapy, the first post-remission therapy was discontinued because of severe cardiovascular complications. She had a relapse of AML with CD33-positive myeloblasts which comprised 38.4 % of the bone marrow cells in November 2007. She received two courses of low-dose chemotherapy because of the previous complications. The amount of Wilm's tumor 1 (WT1) mRNA in the peripheral blood was 13,000 copies/μg RNA after the first course of the chemotherapy, and 4.8 % myeloblasts remained in the bone marrow after the second course. She was treated with a single course of gemtuzumab ozogamicin (GO), with a subsequent CR with 0.9 % marrow myeloblasts and fewer than 50 copies of WT-1 mRNA (normal level). Thereafter, she received five courses of GO monotherapy at each occasion of early AML relapse. Hematological remission has been sustained over a period of about 24 months with the GO monotherapy alone. This case suggests that GO monotherapy is a useful salvage therapy for early relapse of CD33-positive AML in situations in which standard chemotherapy is not indicated.

journal_name

Int J Hematol

authors

Tsunemine H,Akasaka H,Sakane EI,Ito K,Kodaka T,Takahashi T

doi

10.1007/s12185-013-1481-y

subject

Has Abstract

pub_date

2014-02-01 00:00:00

pages

193-7

issue

2

eissn

0925-5710

issn

1865-3774

journal_volume

99

pub_type

杂志文章
  • X-linked lymphoproliferative disease in an adult.

    abstract::X-linked lymphoproliferative disease (XLP) is an inherited immunodeficiency characterized by an extreme susceptibility to Epstein-Barr virus (EBV) infection. Patients with XLP mainly present with the 3 clinical manifestations of fulminant infectious mononucleosis, lymphoproliferative disorder, and dysgammaglobulinemia...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1532/IJH97.05020

    authors: Hoshino T,Kanegane H,Doki N,Irisawa H,Sakura T,Nojima Y,Miyawaki S,Miyawaki T

    更新日期:2005-07-01 00:00:00

  • Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).

    abstract::We evaluated the efficacy and safety of switching to nilotinib in CML-CP patients who had achieved MMR with continuous detectable BCR-ABL1 transcript levels after long-term imatinib treatment. Patients who had achieved MMR, but not deep molecular response (DMR), after > 18 months from the initiation of imatinib receiv...

    journal_title:International journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s12185-018-2401-y

    authors: Ishikawa J,Matsumura I,Kawaguchi T,Kuroda J,Nakamae H,Miyamoto T,Matsuoka KI,Shibayama H,Hino M,Hirase C,Kamimura T,Shimose T,Akashi K,Kanakura Y

    更新日期:2018-05-01 00:00:00

  • Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy.

    abstract::To examine the effects and optimal dose of danazol on idiopathic thrombocytopenic purpura (ITP), we administered a low-medium dose to 14 patients with this disease. A low-medium dose of danazol was effective in maintaining the platelet count at a high level, even after the dose of prednisolone was reduced. A low-mediu...

    journal_title:International journal of hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kondo H,Iseki T,Goto S,Takaso T,Ohto M,Okuda K

    更新日期:1992-06-01 00:00:00

  • Safety, therapeutic effectiveness, and cost of parenteral iron therapy.

    abstract::Patients have to discontinue the use of oral iron therapy due to the development of side effects and lack of long-term adherence to medication for iron deficiency anemia. This study aimed to evaluate the therapeutic effectiveness, safety, and cost of intravenous iron sucrose therapy. The computerized database and medi...

    journal_title:International journal of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s12185-009-0352-z

    authors: Asma S,Boga C,Ozdogu H

    更新日期:2009-07-01 00:00:00

  • Primary plasma cell leukemia followed by testicular plasmacytoma.

    abstract::Plasma cell leukemia (PCL) is a highly aggressive plasma cell disease characterized by a poor prognosis and a low response rate to conventional therapy. Herein, we describe a 69-year-old patient with primary PCL, developing testicular disease while in complete hematological remission, following by muscle involvement a...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-010-0745-z

    authors: Valentini CG,Bozzoli V,Fianchi L,Voso MT,Di Paolantonio G,Criscuolo M,Leone G,Larocca LM,Pagano L

    更新日期:2011-02-01 00:00:00

  • Molecular basis of clonal evolution in multiple myeloma.

    abstract::The treatment outcome of multiple myeloma (MM) is worse than expected from the average numbers of non-synonymous mutations, which are roughly correlated with the prognosis of cancer patients. The refractoriness of MM may be ascribed to the complex genomic architecture and clonal behavior of the disease. In MM, disease...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s12185-020-02829-6

    authors: Furukawa Y,Kikuchi J

    更新日期:2020-04-01 00:00:00

  • Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase

    abstract::Rapid vitamin K antagonist (VKA) reversal is required in patients experiencing major bleeding or requiring urgent surgery. Four-factor prothrombin complex concentrate (4F-PCC; Beriplex®/Kcentra®) was shown in two large randomized controlled, international phase 3b trials to be an effective alternative to plasma for ur...

    journal_title:International journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s12185-017-2311-4

    authors: Kushimoto S,Fukuoka T,Kimura A,Toyoda K,Brainsky A,Harman A,Chung T,Yasaka M

    更新日期:2017-12-01 00:00:00

  • CD34-negative hematopoietic stem cells show distinct expression profiles of homing molecules that limit engraftment in mice and sheep.

    abstract::We and others have reported that human hematopoietic stem cells (HSCs) are also present in the CD34-negative (CD34-) fraction of human cord blood (CB). Here, we examined the hematopoietic engraftment potential of 13 or 18 lineage-negative (13Lin- or 18Lin-) CD34+/- cells from human CB in mice and sheep. Both 13Lin- an...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-017-2290-5

    authors: Abe T,Matsuoka Y,Nagao Y,Sonoda Y,Hanazono Y

    更新日期:2017-11-01 00:00:00

  • A variant form of acute promyelocytic leukemia with marked myelofibrosis.

    abstract::We describe a variant form, French-American-British (FAB) M3v, of acute promyelocytic leukemia (APL; FAB M3) with atypical morphocytochemical features, immature antigens (CD34 and HLA-DR) and marked myelofibrosis (MF). Usual APL cells do not express CD34 or HLA-DR antigens. MF may be more frequently observed in patien...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/BF02982068

    authors: Fukuno K,Tsurumi H,Yoshikawa T,Yamada T,Oyama M,Moriwaki H

    更新日期:2001-10-01 00:00:00

  • Androgen therapy in combination with granulocyte colony-stimulating factor and erythropoietin in a patient with refractory anemia.

    abstract::Initial treatment with androgen (metenolone acetate) alone for 19 weeks had no effect in a 45-year-old Japanese female with refractory anemia (RA). The patient achieved trilineage hematologic recovery after addition of recombinant human granulocyte colony-stimulating factor (G-CSF) and recombinant human erythropoietin...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1016/s0925-5710(96)00530-0

    authors: Katayama Y,Kojima K,Omoto E,Harada M

    更新日期:1996-12-01 00:00:00

  • Excess soluble urokinase-type plasminogen activator receptor in the plasma of patients with paroxysmal nocturnal hemoglobinuria inhibits cell-associated fibrinolytic activity.

    abstract::The plasma levels of soluble urokinase-type plasminogen activator receptor (uPAR; CD87) measured by enzyme-linked immunosorbent assay were higher in patients with paroxysmal nocturnal hemoglobinuria (PNH) (5.8 +/- 4.7 ng/ml, mean +/- S.D., n = 9) than in normal donors (2.0 +/- 0.8 ng/ml, mean +/- S.D., n = 15). The hi...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1016/s0925-5710(96)00559-2

    authors: Ninomiya H,Hasegawa Y,Nagasawa T,Abe T

    更新日期:1997-04-01 00:00:00

  • A complicated translocation involving five chromosomes (Nos. 9, 11, 12, 21 and 22) in a patient with chronic myelocytic leukemia (CML).

    abstract::A new complicated Ph1 translocation involving five chromosomes, t(9;22;21;11;inv ins(12)-(q15p12p13))(q34;q11;q22;q13;q15), was found in a 64-year-old Korean woman with chronic myelocytic leukemia (CML). At presentation, the patient was found to be in the accelerated phase, she entered the chronic phase after six cycl...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:

    authors: Abe R,Shiga Y,Ookoshi T,Tanaka T,Maruyama Y

    更新日期:1991-12-01 00:00:00

  • Severe bleeding tendency caused by leukemic infiltration and destruction of vascular walls in chronic neutrophilic leukemia.

    abstract::Bleeding is reportedly one of the major causes of death in patients with chronic neutrophilic leukemia (CNL), but thrombocytopenia, abnormal platelet functions, or coagulopathy has been confirmed to be the cause of the bleeding tendency in only a small proportion of the patients. We report the case of a 49-year-old wo...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/BF02982088

    authors: Noguchi T,Ikeda K,Yamamoto K,Ashiba A,Yoshida J,Munemasa M,Takenaka K,Shinagawa K,Ishimaru F,Yoshino T,Niiya K,Harada M

    更新日期:2001-12-01 00:00:00

  • An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma.

    abstract::We evaluated the efficacy and toxicity of a new salvage regimen, consisting of rituximab (375 mg/m(2), day 1), ifosfamide (1500 mg/m(2) on days 3-7), etoposide (150 mg/m(2), days 3-5), cytarabine (100 mg/m(2), days 3-5) and dexamethasone (40 mg/body, days 3-5) (R-IVAD) for relapsed or refractory aggressive B-cell lymp...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-011-0884-x

    authors: Miura K,Takei K,Kobayashi S,Kiso S,Hirabayashi Y,Hojo A,Kodaira H,Yagi M,Kurita D,Kobayashi Y,Tanaka T,Iriyama N,Hatta Y,Kura Y,Yamazaki T,Sawada U,Takeuchi J

    更新日期:2011-07-01 00:00:00

  • Ph1-positive acute lymphoblastic leukemia associated with an isochromosome 17q.

    abstract::We report a patient with Ph1-positive acute lymphoblastic leukemia (ALL) having i(17q) in whom bony lesions were the initial clinical manifestation. The patient was a 53-year-old male who began to have pains in his left hip early in March 1985. Relevant findings on admission included: WBC 21,300/microliters; blast cel...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Kageyama T,Takiuchi H,Hasegawa M,Ohyabu H,Horiike S

    更新日期:1991-06-01 00:00:00

  • Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts.

    abstract::The percentage of myeloperoxidase (MPO)-positive blast cells is a simple and highly significant prognostic factor in AML patients. It has been reported that the high MPO group (MPO-H), in which >50% of blasts are MPO activity positive, is associated with favorable karyotypes, while the low MPO group (≤50% of blasts ar...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-011-0883-y

    authors: Tominaga-Sato S,Tsushima H,Ando K,Itonaga H,Imaizumi Y,Imanishi D,Iwanaga M,Taguchi J,Fukushima T,Yoshida S,Hata T,Moriuchi Y,Kuriyama K,Mano H,Tomonaga M,Miyazaki Y

    更新日期:2011-07-01 00:00:00

  • XCIND as a genetic disease of X-irradiation hypersensitivity and cancer susceptibility.

    abstract::The XCIND syndrome is named after distinct hypersensitivity to ionizing (X-ray) irradiation, cancer susceptibility, immunodeficiency, neurological abnormality, and double-strand DNA breakage. The disorders comprising XCIND syndrome are usually inherited in an autosomal recessive manner. Ataxia telangiectasia (A-T) is ...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s12185-012-1240-5

    authors: Mizutani S,Takagi M

    更新日期:2013-01-01 00:00:00

  • Clinical characteristics and computed tomography findings of pulmonary toxoplasmosis after hematopoietic stem cell transplantation.

    abstract::The prognosis of pulmonary toxoplasmosis, including disseminated toxoplasmosis involving the lungs, following hematopoietic stem cell transplantation (HSCT) is extremely poor due to the difficulties associated with early diagnosis and the rapidly progressive deterioration of multiorgan function. In our institution, we...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-016-2077-0

    authors: Sumi M,Norose K,Hikosaka K,Kaiume H,Takeda W,Kirihara T,Kurihara T,Sato K,Ueki T,Hiroshima Y,Kuraishi H,Watanabe M,Kobayashi H

    更新日期:2016-12-01 00:00:00

  • Characteristics of methotrexate-induced stroke-like neurotoxicity.

    abstract::Intrathecal administration of methotrexate (IT-MTX) can lead to neurotoxicity. MTX-induced neurotoxicity occasionally manifests with a stroke-like presentation that is difficult to distinguish from genuine stroke. We retrospectively reviewed records of nine patients with leukemia or lymphoma and episodes of stroke-lik...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-018-2525-0

    authors: Watanabe K,Arakawa Y,Oguma E,Uehara T,Yanagi M,Oyama C,Ikeda Y,Sasaki K,Isobe K,Mori M,Hanada R,Koh K

    更新日期:2018-12-01 00:00:00

  • Molecular remission achieved by interferon therapy in a patient with cytogenetically relapsed chronic myelogenous leukemia after syngeneic bone marrow transplantation.

    abstract::A patient with chronic myelogenous leukemia (CML) in chronic phase (CP) had been treated with a syngeneic bone marrow transplantation (BMT). Cytogenetic remission was confirmed 3 months later. One year after transplantation, hematological remission persisted while cytogenetic analysis revealed a recurrence of Philadel...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1016/0925-5710(96)00486-0

    authors: Yano K,Iijima K,Sao H,Kobayashi M

    更新日期:1996-10-01 00:00:00

  • Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma.

    abstract::Bortezomib is a proteasome inhibitor demonstrating substantial activity in multiple myeloma. One of its key toxicities is peripheral neuropathy, which is reversible in most patients. The possibility that bortezomib might in rare cases induce severe neuropathies by auto-inflammatory mechanisms remains controversial. We...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-011-0847-2

    authors: Schmitt S,Goldschmidt H,Storch-Hagenlocher B,Pham M,Fingerle-Rowson G,Ho AD,Neben K

    更新日期:2011-06-01 00:00:00

  • EBV-positive PEL-like lymphoma that developed in the course of antisynthetase syndrome treated with tacrolimus.

    abstract::Primary effusion lymphoma (PEL) is a rare type of extranodal lymphoma, typically of a B-cell origin, which presents as lymphomatous effusion with no nodal enlargement or tumor masses. The development PEL is universally associated with human herpes virus-8 (HHV-8) infection. Cases of HHV-8-negative primary lymphomatous...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-018-2426-2

    authors: Okada K,Asakura S,Yano T,Kishimoto T

    更新日期:2018-09-01 00:00:00

  • Mesenchymal stem cells in cancer: tumor-associated fibroblasts and cell-based delivery vehicles.

    abstract::Recent evidence suggests that mesenchymal stem cells (MSC) selectively home to tumors, where they contribute to the formation of tumor-associated stroma. This effect can be opposed by genetically modifying MSC to produce high levels of anti-cancer agents that blunt tumor growth kinetics and inhibit the growth of tumor...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1532/IJH97.06230

    authors: Hall B,Dembinski J,Sasser AK,Studeny M,Andreeff M,Marini F

    更新日期:2007-07-01 00:00:00

  • Multiple myeloma presenting as bilateral breast lumps in pregnant woman.

    abstract:BACKGROUND:Multiple myeloma (MM) is a systemic disease in the elderly. Its incidence in patients younger than 40 years old and especially in pregnant women is extremely rare. MM may involve extraosseous sites, and only in rare cases it is observed in the breast. CASE REPORT:We describe the case of a 39-year-old woman ...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-013-1420-y

    authors: Bouzguenda R,Khanfir A,Toumi N,Chaaben K,Hentati Y,Ayadi L,Feki W,Daoud J,Frikha M

    更新日期:2013-10-01 00:00:00

  • Serial morphologic observation of bone marrow in aplastic anemia in children.

    abstract::Recent reports of myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) developing after treatment with immunosuppressants and granulocyte colony-stimulating factor (G-CSF) has raised the question of whether previously unrecognized myelodysplastic features had been present or whether actual transformation had oc...

    journal_title:International journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1532/ijh97.04178

    authors: Bessho F,Imashuku S,Hibi S,Tsuchida M,Nakahata T,Miyazaki S,Kojima S,Tsukimoto I,Hamajima N,Pediatric AA Follow-up Study Group in Japan.

    更新日期:2005-06-01 00:00:00

  • Myelodysplastic syndrome in a patient with a unique constitutional chromosome abnormality t(2;11) (q31;p13).

    abstract::We present a case of myelodysplastic syndrome (MDS), which developed into an overt leukemic phase in a 15-year-old female with a rare constitutional abnormality [46,XX,t(2;11) (q31;p13)]. The patient entered complete remission after 3 months of chemotherapy. On chromosome analysis during remission, the t(2;11) (q31;p1...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:

    authors: Hinoda Y,Itoh H,Takahashi T,Adachi M,Tsujisaki M,Imai K,Yachi A

    更新日期:1992-08-01 00:00:00

  • Extranodal multifocal Rosai-Dorfman disease: response to 2-chlorodeoxyadenosine treatment.

    abstract::Rosai-Dorfman disease (RDD) or "sinus histiocytosis with massive lymphadenopathy" is a rare lymphoproliferative disorder of unknown etiology. The disease usually presents with painless lymphadenopathy with occasional extranodal involvement in various organs. We report a case of a 36-year-old man with a history of non-...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-008-0192-2

    authors: Konca C,Özkurt ZN,Deger M,Akı Z,Yağcı M

    更新日期:2009-01-01 00:00:00

  • Identification of anti-thrombopoietin receptor antibody in prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation treated successfully with eltrombopag.

    abstract::A 55-year-old female with stage IVA follicular lymphoma in third complete remission underwent allogeneic peripheral blood stem cell transplantation. Neutrophil engraftment was achieved on day +18; however, platelet counts remained below 10 × 10(3)/µL, necessitating transfusions twice a week for more than 3 months. Bon...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-015-1806-0

    authors: Fujimi A,Kamihara Y,Hashimoto A,Kanisawa Y,Nakajima C,Hayasaka N,Yamada S,Okuda T,Minami S,Ono K,Iyama S,Kato J

    更新日期:2015-10-01 00:00:00

  • Pathophysiology and treatment of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS).

    abstract::The central pathogenic feature of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) is the formation of platelet aggregates, perhaps by damaged endothelial cells. The evidence for endothelial cell damage has been supported by multiple findings, including the harmful effects of TTP/HUS plasma, whi...

    journal_title:International journal of hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Kakishita E

    更新日期:2000-06-01 00:00:00

  • A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.

    abstract::Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in pregnant women. Enoxaparin is a low-molecular-weight heparin used during pregnancy to treat or prevent VTE. In this study, we compare anti-factor Xa peak levels in pregnant and non-pregnant women, and explore the association between anti-fac...

    journal_title:International journal of hematology

    pub_type: 杂志文章

    doi:10.1007/s12185-020-02873-2

    authors: Aleidan FAS,Aljarba GA,Aldakhil AA,Allehyani BI,Yahia MA,Alghtani NE,Badri M,Alaklabi AA,Alsuhaibani A,Crowther MA

    更新日期:2020-07-01 00:00:00